These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30733273)

  • 1. The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
    Hicks SW; Tarantelli C; Wilhem A; Gaudio E; Li M; Arribas AJ; Spriano F; Bordone R; Cascione L; Lai KC; Qiu Q; Taborelli M; Rossi D; Stussi G; Zucca E; Stathis A; Sloss CM; Bertoni F
    Haematologica; 2019 Aug; 104(8):1633-1639. PubMed ID: 30733273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
    Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
    Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
    Blanc V; Bousseau A; Caron A; Carrez C; Lutz RJ; Lambert JM
    Clin Cancer Res; 2011 Oct; 17(20):6448-58. PubMed ID: 22003072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.
    Tarantelli C; Wald D; Munz N; Spriano F; Bruscaggin A; Cannas E; Cascione L; Gaudio E; Arribas AJ; Manjappa S; Golino G; Scalise L; Cacciapuoti MT; Zucca E; Stathis A; Inghirami G; Van Berkel PH; Rossi D; Caimi PF; Zammarchi F; Bertoni F
    Haematologica; 2024 Oct; 109(10):3314-3326. PubMed ID: 38721745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
    Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB
    Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.
    Raufi A; Ebrahim AS; Al-Katib A
    Cancer Manag Res; 2013; 5():225-33. PubMed ID: 24023523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.
    Trnĕný M; Verhoef G; Dyer MJ; Ben Yehuda D; Patti C; Canales M; Lopez A; Awan FT; Montgomery PG; Janikova A; Barbui AM; Sulek K; Terol MJ; Radford J; Guidetti A; Di Nicola M; Siraudin L; Hatteville L; Schwab S; Oprea C; Gianni AM
    Haematologica; 2018 Aug; 103(8):1351-1358. PubMed ID: 29748443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment.
    Li Z; Wang M; Yao X; Li H; Li S; Liu L; Yu D; Li X; Fang J; Huang C
    Int Immunopharmacol; 2018 Sep; 62():299-308. PubMed ID: 30048860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.
    Chang CA; Emberley E; D'Souza AL; Zhao W; Cosgrove C; Parrish K; Mitra D; Payson E; Oleksijew A; Ellis P; Rodriguez L; Duggan R; Hrusch C; Lasko L; Assaily W; Zheng P; Liu W; Hernandez A; McCarthy K; Zhang Z; Rha G; Cao Z; Li Y; Perng O; Campbell J; Zhang G; Curran T; Bruncko M; Marvin CC; Hobson A; McPherson M; Uziel T; Pysz MA; Zhao X; Bankovich A; Hayflick J; McDevitt M; Freise KJ; Morgan-Lappe S; Purcell JW
    Blood; 2024 Aug; 144(7):757-770. PubMed ID: 38701407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Kantarjian HM; Lioure B; Kim SK; Atallah E; Leguay T; Kelly K; Marolleau JP; Escoffre-Barbe M; Thomas XG; Cortes J; Jabbour E; O'Brien S; Bories P; Oprea C; Hatteville L; Dombret H
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):139-45. PubMed ID: 26775883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay.
    Lai KC; Deckert J; Setiady YY; Shah P; Wang L; Chari R; Lambert JM
    Pharm Res; 2015 Nov; 32(11):3593-603. PubMed ID: 25630819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
    Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
    Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugate technology development for hematologic disorders.
    Bander NH; Czuczman MS; Younes A
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
    Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
    Cheng X; Li J; Tanaka K; Majumder U; Milinichik AZ; Verdi AC; Maddage CJ; Rybinski KA; Fernando S; Fernando D; Kuc M; Furuuchi K; Fang F; Uenaka T; Grasso L; Albone EF
    Mol Cancer Ther; 2018 Dec; 17(12):2665-2675. PubMed ID: 30262588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
    Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
    Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
    Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.